Repair

What's in it

The combination logic

The idea behind combining these two is that they cover different parts of the healing process. BPC-157 is thought to calm inflammation and protect tissue broadly. TB-500 is thought to help cells move to where they’re needed and encourage new blood vessels to form, bringing more blood flow — and more of what a tissue needs to heal — to an injured area. Used together, one is protecting while the other is rebuilding. Clinical detail: BPC-157’s proposed mechanism centers on upregulation of growth-hormone receptor expression in fibroblasts and modulation of the VEGFR2-Akt-eNOS pathway supporting angiogenesis and cell migration, alongside broad cytoprotective and anti-inflammatory effects. TB-500 (Tβ4 fragment) acts primarily through actin regulation, promoting cell motility, differentiation, and angiogenesis via upregulation of VEGF and matrix metalloproteinases. The two mechanisms are non-overlapping — angiogenic support (TB-500) paired with broader tissue protection and independent pro-angiogenic signaling (BPC-157) — which is the stated rationale for pairing rather than redundancy.

Is there evidence for the combination, or only for the parts? Each individual peptide has a body of laboratory research behind its proposed repair mechanisms. Neither has been tested in a randomized controlled human trial for any indication, and no study, in the laboratory or in people, has tested this specific two-peptide combination against either peptide alone. The rationale for pairing them is mechanistic (non-overlapping pathways), not the result of a comparative trial. That is not the same as saying it does not work — but it does mean the combination itself is unproven, even where the individual components have supportive laboratory research.

What it's used for

Overlaps & stacked risks

• Both peptides carry their individual risk profiles in addition to each other — this is not a case of one offsetting the other’s risk.
• TB-500’s angiogenic mechanism is a theoretical amplifying factor if any undiagnosed abnormal tissue growth is present.
• Neither peptide has long-term human safety data at any dose, let alone in combination.
• Injection-site reactions are the most commonly reported effect for both peptides individually.

Who it is not for

• Pregnant or breastfeeding patients
• Anyone with a personal or family history of cancer — TB-500’s blood-vessel-growth mechanism is a theoretical concern for feeding tumor growth
• Anyone on anticoagulant or antiplatelet medication without provider review
• Competitive athletes subject to anti-doping testing — both peptides are prohibited in-competition

Who it suits

Patients recovering from a soft-tissue injury (tendon, ligament, or muscle) who have discussed with their provider that it has not been tested in people and are not in one of the excluded groups above. Not a substitute for physical therapy, surgical repair where indicated, or a documented recovery plan.

Who makes this, and under what rules

Everything dispensed here is prepared by a licensed 503A compounding pharmacy — not bought from a supplier and repackaged, and not sourced from an online seller. That designation carries specific, enforceable obligations:

• A prescription in your name. Compounded from a prescription for one identified patient, after an evaluation.
• Licensed and inspected. A state license, subject to inspection by the state board of pharmacy.
• Sterile preparation to a published standard. USP standards.
• A paper trail. A lot number and beyond-use date on every preparation.

A compounded preparation is not an FDA-approved medicine — but it is the difference between a licensed pharmacy working to a standard and an unregulated website. This page describes Repair for general educational purposes. It is not medical advice and does not replace a consultation with a licensed provider. Individual results vary, and combination products carry the risks of each included peptide.